BMI

CopilotIQ Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Cardiology, Software, General Health, Health, Diabetes, Artificial Intelligence, Health Technology, Technology, Blood pressure, Glucose, Editorial, Culture, Organization, Entrepreneurship, MIC, Physician, Biomarker, AI, Hope, Anomaly, Fasting, Hyperglycemia, ITunes, Most, Medicare, BMI, Nursing, Medicare Advantage, Hypertension, Human, Pharmaceutical industry

CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.

Key Points: 
  • CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

Audacy Provides Strong Performance Update Following Restructuring Plan Approval

Retrieved on: 
Tuesday, March 12, 2024
Entertainment, Communications, Technology, TV and Radio, Audio, Video, Podcast, Media, Wondery, FCC, Netflix, Sport, Digital, Acceleration, Puck, Sale, Art, The New York Times, FT, Wall, Metropolitan Museum of Art, Corporate action, BMI, Music

Audacy, Inc. (the “Company” or “Audacy”) is pleased to report a strong start to 2024, driving significant sequential acceleration across key financial metrics and performance indicators.

Key Points: 
  • Audacy, Inc. (the “Company” or “Audacy”) is pleased to report a strong start to 2024, driving significant sequential acceleration across key financial metrics and performance indicators.
  • The Company is providing this update to deliver additional visibility on its progress since receiving court approval of its consensual pre-packaged Plan of Reorganization on February 20, after just six weeks.
  • The Company now awaits FCC approval to complete its restructuring and plans to file its 2023 10-K later this month.
  • “Audacy is off to a strong start in 2024, driving accelerated financial and operating performance, including solid early growth in revenues, key digital metrics, and audience and revenue shares,” said David Field, Chairman, President and Chief Executive Officer, Audacy.

L-Nutra's Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology

Retrieved on: 
Thursday, April 4, 2024
Glycated hemoglobin, Metabolism, FMD, Type 2 diabetes, Disease, Insulin, Diabetes, Patient, Research, Fasting, Standard of care, Food, Doctor of Philosophy, Diet, Insulin resistance, Clinical trial, Type 2, Safety, Waist, BMI, Metformin, Movement, Prediabetes, Pharmaceutical industry

This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.

Key Points: 
  • This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.
  • Glycemic Management: FMD participants demonstrated superior glycemic management, with 53% showing improvement, compared to only 8% in the control group.
  • L-Nutra's patented and clinically backed nutrition technology food formulations are effective in supporting metabolism, cell renewal, and muscle protection by mimicking the reset and rejuvenation pathways of fasting.
  • "With the Fasting Mimicking Diet, we have successfully enhanced the natural rejuvenating power of fasting with food which has made the regression and remission of diabetes within every patient's reach.

Ketogenic Diet Shows Promise in Treating Serious Mental Illness in Stanford Medicine Study

Retrieved on: 
Monday, April 1, 2024
Overweight, Metabolism, Adipose tissue, Obesity, Schizophrenia, Dyslipidemia, McLean Hospital, Weight gain, Patient, SAN, Mental health, Sleep, Research, University, MD, Quality of life, Eating disorder, DSM-IV codes, Insulin resistance, Body mass index, Clinical trial, Metabolic syndrome, University of Edinburgh, Rethinking, Mood disorder, Psychiatry Research, Ketosis, Waist, BMI, Pharmaceutical industry

SAN MATEO, Calif., April 1, 2024 /PRNewswire/ -- The field of psychiatry may have a new ally in the form of a medical ketogenic diet, according to the findings of a pioneering pilot study published in Psychiatry Research and announced today by Stanford Medicine. The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965. 

Key Points: 
  • The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965.
  • The results offer compelling evidence of the potential benefits of ketogenic dietary therapy in this population.
  • Key findings of the single-arm pilot trial include:
    100% of participants who met the criteria for metabolic syndrome were in remission by the end of the study.
  • Dr. Sethi shared: "These results are encouraging and suggest that a ketogenic diet intervention could serve as a valuable adjunctive treatment for individuals living with serious mental illness.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Human Genome Project, WGS, Blood pressure, Genomics, Health, Certification, Informatics, Founders Fund, Genetic testing, Risk, Genetics, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1

NEW YORK, March 25, 2024 /PRNewswire/ -- Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer's entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina's NovaSeq X Plus, the sequencing company's newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

HNRC REPORTS RESULTS FOR PERIOD ENDING DECEMBER 31, 2023

Retrieved on: 
Tuesday, March 19, 2024
Permian, KCC, Non, HNRC, Copper, Gold, CML, Acquisition, Barrel, Engineering, OTC, Lithium, Skeena, BMI, Fitch Ratings, Placer, Mining

HOUSTON, March 19, 2024 /PRNewswire/ -- Houston Natural Resources Corp. (OTC: HNRC) ("HNR or the Company") announced today results for the year ending December 31, 2023. 

Key Points: 
  • HOUSTON, March 19, 2024 /PRNewswire/ -- Houston Natural Resources Corp. (OTC: HNRC) ("HNR or the Company") announced today results for the year ending December 31, 2023.
  • Financial Results: Twelve Months December 31, 2023 vs Twelve Months December 31, 2022
    Earnings per share for twelve months were $ 0.06 per share.
  • The company has a net asset value of $ 0.42 per share as of December 31, 2023.
  • As of September 30, 2023, total assets of LHO were $70.4 million ( www.hnra-nyse.com )
    HNRC acquired a 40% interest in Rhino Energy Pty Ltd ("Rhino").

BMI Imaging Exhibits At ACCCA 2024 Conference in Orange County

Retrieved on: 
Wednesday, March 13, 2024
Book, BMI, Record, Music

SUNNYVALE, Calif., March 13, 2024 /PRNewswire-PRWeb/ -- BMI Imaging Systems headed to Orange County, California for the 2024 Association of California Community College Administrators (ACCCA) conference. The ACCCA celebrated its 48th annual conference this year. The ACCCA is "a non-profit organization dedicated to the advancement of administrator's rights" and its mission is to "develop and support current and future California community college administrators through professional development, networking and advocacy."

Key Points: 
  • SUNNYVALE, Calif., March 13, 2024 /PRNewswire-PRWeb/ -- BMI Imaging Systems headed to Orange County, California for the 2024 Association of California Community College Administrators (ACCCA) conference.
  • The ACCCA celebrated its 48th annual conference this year.
  • BMI is helping them improve their operations and ability to carry out their responsibilities in a more productive and effective way.
  • Over the decades, BMI has worked with higher education organizations to provide solutions for their document management needs.

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

Retrieved on: 
Tuesday, March 12, 2024
Control, Single-frequency network, Conference, ATTD, Disease, Risk, Weight loss, Blood, Diabetes, Doctor of Philosophy, MD, Type 2 diabetes, Vaccination, A1C, BMI, Prediabetes, Medical device

NEW YORK, March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy.

Key Points: 
  • Dario's cardiometabolic solution integrates digital tools, connected devices and intelligent technologies to deliver a personalized and integrated experience to help drive better outcomes through effective behavior change.
  • Today, members can utilize the Dario solution with or without a GLP-1 medication and receive support tailored to their unique need.
  • The first study presented at ATTD analyzed the data of members engaged in Dario's cardiometabolic solution to manage pre-diabetes, a condition that requires weight loss and regulation of A1c.
  • A second Dario study presented at ATTD evaluated the effectiveness of Dario's digital health solution as a means to improve flu vaccine awareness and rates.

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Retrieved on: 
Monday, March 11, 2024
QIDP, Rifabutin, Face, Patent, Patient, Amoxicillin, Regulatory affairs, Helicobacter pylori, Gastroenterology, Omeprazole, Senior, BMI, FDA, TEL, GAIN, Pharmaceutical industry

TEL AVIV, Israel and RALEIGH, N.C., March 11, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori (H. pylori) infection (Patent No. 11,931,463 to be issued March 19, 20244). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, which affects approximately 35% of the U.S. adult population and this patent is expected to provide protection for Talicia until February 12, 2034.

Key Points: 
  • 11,931,463 to be issued March 19, 20244).
  • Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, which affects approximately 35% of the U.S. adult population and this patent is expected to provide protection for Talicia until February 12, 2034.
  • "Talicia is the only FDA-approved rifabutin-containing all-in-one therapy for the eradication of H. pylori.
  • Its components and formulation are optimized to provide patients with the right medications for successful H. pylori eradication with an optimized resistance profile, which is significant in the face of growing microbial resistance to clarithromycin-based regimens," said Patricia Anderson, RedHill's Senior Vice President of Regulatory Affairs.

What is metabolism? A biochemist explains how different people convert energy differently − and why that matters for your health

Retrieved on: 
Friday, April 5, 2024
Blood pressure, Agonal respiration, Dicarboxylic acid, Kynurenine, Health, Metabolism, Burn, COVID, Obesity, Sport, Exercise, Cell, Multiple sclerosis, Diabetes, COVID-19, Patient, Inflammation, Social media, Mitochondrion, Fats, Electron, Radiation exposure, Food, Carbohydrate, Smoke, Anti-transglutaminase antibodies, Medicine, Protein, Athlete, Carbon, Coenzyme A, Phenotype, Oxygen, Metabolic syndrome, BMI, Blood, Ageing, Medical device

But what exactly is your metabolism?

Key Points: 
  • But what exactly is your metabolism?
  • Everything you expose your body to – from lifestyle to an airborne virus – influences your physical characteristics, such as your blood pressure and energy levels.

Metabolism is energy conversion

  • At the chemical level, energy metabolism begins when the three macronutrients – carbohydrates, fats and protein – are broken down atom by atom to release electrons from chemical bonds.
  • Simply put, a primary role of metabolism is to convert chemical energy into electrical energy and back into chemical energy.
  • I am a biochemist who studies the various networks of metabolism that are used as your body changes.
  • My team and I have been able to define specific traits of metabolism, such as the presence and amount of certain metabolites – products made from breaking down macronutrients – across a wide range of conditions.

Elite athletes define the upper limits

  • Elite athletes offer a prime population to study metabolic function at its best, since their network of molecular and chemical reactions must be finely tuned to compete on the world stage.
  • Traditionally, lactate threshold has been a critical measure of athletic performance by pinpointing exercise intensity when lactate starts to rise in muscles and blood.
  • When comparing the lactate thresholds of a group of elite cyclists, we found that the cyclists with higher thresholds had markers of better mitochondrial function.

Dysfunctional metabolism in diseases like COVID-19

  • Your metabolism also changes if you get an acute illness such as COVID-19.
  • In contrast to elite cyclists, COVID-19 patients have an impaired ability to burn fat that appears to persist with long COVID.


Burning fat uses a lot of oxygen. COVID-19 damages the red blood cells that deliver oxygen to organs. Because red blood cells have a limited ability to repair themselves, they might not function as well during the remainder of their roughly 120-day life span. This may partially explain why COVID symptoms last as long as they do in some people.

Blood donors define the middle

  • Blood donors, coming from every walk of life, also have a diverse range of biological traits as a study population.
  • My team and I looked at blood from over 13,000 blood donors to shed light on their metabolic diversity.
  • We found that blood from donors with higher levels of kynurenine was less likely to restore hemoglobin levels in transfusion recipients compared with donors with lower kynurenine levels.


In addition to his appointment at the University of Colorado, Travis Nemkov is an Affiliate Investigator of Vitalant Research Institute and a co-founder of Omix Technologies.